Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Jessica K. Roydhouse"'
Autor:
Jessica K. Roydhouse PhD, Ira B. Wilson MD MSc, Roee Gutman PhD, Robert B. Wallace MD MSc, Tara Berman MD MS, Nancy L. Keating MD MPH
Publikováno v:
Journal of Patient Experience, Vol 8 (2021)
The aim was to examine the association of patient-reported physician awareness of biological CAM use and patient perceptions of care experience and quality with a population-based study of patients with incident lung and colorectal cancer. This was a
Externí odkaz:
https://doaj.org/article/aba68155be9e487a94114d603127c9f6
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background Proxy respondents are frequently used in surveys, including those assessing health-related quality of life (HRQOL). In cancer, most research involving proxies has been undertaken with paired proxy-patient populations, where proxy
Externí odkaz:
https://doaj.org/article/19f0b5064eb44cf7adab914681ec5ced
Autor:
Paul G. Kluetz, Pallavi S. Mishra-Kalyani, Vishal Bhatnagar, Rajeshwari Sridhara, Jessica K Roydhouse, Roee Gutman, Bellinda L King-Kallimanis
Publikováno v:
Value in Health. 24:822-829
Unblinded trials are common in oncology, but patient knowledge of treatment assignment may bias response to questionnaires. We sought to ascertain the extent of possible bias arising from patient knowledge of treatment assignment.This is a retrospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f3635314edca3aaa8f7293e924d1da
https://doi.org/10.1016/j.jval.2020.12.015
https://doi.org/10.1016/j.jval.2020.12.015
Autor:
Madeleine King, Véronique Sébille, Angelos P. Kassianos, Isoqol Proxy Task Force, Henrik Eshøj, Allan Berrocal, Emre Yucel, Jessica K Roydhouse, Katarzyna Wac, Rebecca Mercieca-Bebber, Claudia Rutherford, Alyssa M. Lanzi, Natasha Roberts, Nadia Corsini, Cindy J. Nowinski, Matthew L. Cohen
Publikováno v:
Roydhouse, J K, Cohen, M L, Eshoj, H R, Corsini, N, Yucel, E, Rutherford, C, Wac, K, Berrocal, A, Lanzi, A, Nowinski, C, Roberts, N, Kassianos, A P, Sebille, V, King, M T, Mercieca-Bebber, R & on behalf of the ISOQOL Proxy Task Force and the ISOQOL Board of Directors 2022, ' The use of proxies and proxy-reported measures : a report of the international society for quality of life research (ISOQOL) proxy task force ', Quality of Life Research, vol. 31, no. 2, pp. 317-327 . https://doi.org/10.1007/s11136-021-02937-8
Aims: Proxy reports are often used when patients are unable to self-report. It is unclear how proxy measures are currently in use in adult health care and research settings. We aimed to describe how proxy reports are used in these settings, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53982020cdd1145626c97fb1f1713a6d
https://hdl.handle.net/11541.2/25632
https://hdl.handle.net/11541.2/25632
Autor:
Mallorie H Fiero, Jessica K Roydhouse, Vishal Bhatnagar, Ting-Yu Chen, Bellinda L King-Kallimanis, Shenghui Tang, Paul G Kluetz
Publikováno v:
The Lancet. Oncology. 23(5)
Time-to-event endpoints for patient-reported outcomes, such as time to deterioration of symptoms or function, are frequently used in cancer clinical trials. Although time-to-deterioration endpoints might seem familiar to cancer researchers for being
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e08202f041c5a2cc4fda7be2b0f5f9
https://pubmed.ncbi.nlm.nih.gov/35489354
https://pubmed.ncbi.nlm.nih.gov/35489354
Autor:
Roee Gutman, Ira B. Wilson, Jessica K Roydhouse, Tara Berman, Nancy L. Keating, Robert B. Wallace
Publikováno v:
Journal of Patient Experience
Journal of Patient Experience, Vol 8 (2021)
Journal of Patient Experience, Vol 8 (2021)
The aim was to examine the association of patient-reported physician awareness of biological CAM use and patient perceptions of care experience and quality with a population-based study of patients with incident lung and colorectal cancer. This was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c59756031af984e5bb121c01cf4b85
https://pubmed.ncbi.nlm.nih.gov/34722868
https://pubmed.ncbi.nlm.nih.gov/34722868
Publikováno v:
Am J Drug Alcohol Abuse
Relapse rates among individuals with substance use disorder (SUD) remain high and new treatment approaches are needed, which require evaluation in randomized controlled trials (RCTs). Measurement and interpretation challenges for SUD RCT data are oft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a74dfd038d87ed22a54991e859aea558
https://europepmc.org/articles/PMC10124131/
https://europepmc.org/articles/PMC10124131/
Publikováno v:
Health Services and Outcomes Research Methodology. 20:40-59
Patient-reported outcome and experience measures are increasingly important in health care and health research. The use of these measures is growing in the US and overseas, and performance measures that incorporate patient-reported outcomes are being
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dda0482f9f5b2ce82a9a43c49f927846
https://doi.org/10.1007/s10742-019-00205-4
https://doi.org/10.1007/s10742-019-00205-4
Autor:
Mallorie H. Fiero, Paul G. Kluetz, Jonathon Vallejo, Rajeshwari Sridhara, Jessica K Roydhouse, Bellinda L. King-Kallimanis
Publikováno v:
The Lancet Oncology. 20:e582-e589
With the advent of patient-focused drug development, the US Food and Drug Administration (FDA) has redoubled its efforts to review patient-reported outcome (PRO) data in cancer trials submitted as part of a drug's marketing application. This Review a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e860c2c74dc4dbd5c4222691e4000d9e
https://doi.org/10.1016/s1470-2045(19)30335-3
https://doi.org/10.1016/s1470-2045(19)30335-3
Autor:
Harpreet Singh, Gideon M. Blumenthal, Jessica K Roydhouse, Marc R. Theoret, Bellinda L King-Kallimanis, Lynn J. Howie, Paul G. Kluetz
Publikováno v:
Clinical Trials. 16:322-326
Background Patient-reported outcome measures can be used to capture the patient’s experience with disease and treatment. Immunotherapy agents including the anti-programmed death receptor-1/programmed death-ligand-1 inhibitor therapies have unique s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e24c805c3b00b52ae0b7ade7590d11b8
https://doi.org/10.1177/1740774519836991
https://doi.org/10.1177/1740774519836991